Tags

Type your tag names separated by a space and hit enter

Duration of bronchoprotection of the long-acting muscarinic antagonists tiotropium & glycopyrronium against methacholine-induced bronchoconstriction in mild asthmatics.
Respir Med. 2016 09; 118:96-101.RM

Abstract

The duration of bronchoprotection against methacholine-induced bronchoconstriction by long-acting muscarinic antagonists (LAMA's) in asthmatics and whether these drugs differ in their pharmacodynamic properties remain to be determined. The most recent published guidelines for methacholine challenge testing (MCT) suggest that LAMA's should be abstained from for 48 h prior to testing, perhaps one week in the case of tiotropium. The objectives were to determine and compare the duration of protection of a single dose of two different LAMA's, tiotropium and glycopyrronium, against methacholine-induced bronchoconstriction. Thirteen mild-to-moderate asthmatics [with a forced expiratory volume in 1 s (FEV1) > 65% of predicted and a baseline methacholine provocation concentration causing a 20% reduction in FEV1 (PC20) ≤ 8 mg/mL] completed this double-blind, double-dummy, crossover study. Methacholine challenges were performed before treatment (5 μg tiotropium or 50 μg glycopyrronium) and at 1, 24, 48, 72, 96 and 168 h post-treatment. The minimum duration between treatment administration was 11 days. Both drugs provided significant bronchoprotection, each producing greater than a 16-fold increase in mean PC20 by 1 h. Tiotropium still provided statistically significant protection at 7 days (p = 0.0282) while glycopyrronium provided bronchoprotection until day 7 (p = 0.0590). Tiotropium provided statistically superior bronchoprotection at 24 and 72 h compared to glycopyrronium. To minimize the occurrence of false negatives, MCT guidelines should be updated to recommend a minimum one-week abstinence period from all LAMA's. MCT was also able to statistically differentiate between tiotropium and glycopyrronium with respect to the degree and duration of bronchoprotection provided by each.

CLINICAL TRIAL REGISTRATION NUMBER

NCT02622243.

Authors+Show Affiliations

University of Saskatchewan, College of Medicine, Department of Physiology, 107 Wiggins Road, Saskatoon, SK S7N 5E5, Canada.University of Saskatchewan, College of Medicine, Department of Physiology, 107 Wiggins Road, Saskatoon, SK S7N 5E5, Canada; University of Saskatchewan, Department of Medicine, Division of Respirology, Critical Care and Sleep Medicine, 103 Hospital Drive, Saskatoon, SK S7N 0W8, Canada.University of Saskatchewan, College of Medicine, Department of Physiology, 107 Wiggins Road, Saskatoon, SK S7N 5E5, Canada; University of Saskatchewan, Department of Medicine, Division of Respirology, Critical Care and Sleep Medicine, 103 Hospital Drive, Saskatoon, SK S7N 0W8, Canada. Electronic address: don.cockcroft@usask.ca.

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

27578477

Citation

Blais, Christianne M., et al. "Duration of Bronchoprotection of the Long-acting Muscarinic Antagonists Tiotropium & Glycopyrronium Against Methacholine-induced Bronchoconstriction in Mild Asthmatics." Respiratory Medicine, vol. 118, 2016, pp. 96-101.
Blais CM, Davis BE, Cockcroft DW. Duration of bronchoprotection of the long-acting muscarinic antagonists tiotropium & glycopyrronium against methacholine-induced bronchoconstriction in mild asthmatics. Respir Med. 2016;118:96-101.
Blais, C. M., Davis, B. E., & Cockcroft, D. W. (2016). Duration of bronchoprotection of the long-acting muscarinic antagonists tiotropium & glycopyrronium against methacholine-induced bronchoconstriction in mild asthmatics. Respiratory Medicine, 118, 96-101. https://doi.org/10.1016/j.rmed.2016.07.017
Blais CM, Davis BE, Cockcroft DW. Duration of Bronchoprotection of the Long-acting Muscarinic Antagonists Tiotropium & Glycopyrronium Against Methacholine-induced Bronchoconstriction in Mild Asthmatics. Respir Med. 2016;118:96-101. PubMed PMID: 27578477.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Duration of bronchoprotection of the long-acting muscarinic antagonists tiotropium & glycopyrronium against methacholine-induced bronchoconstriction in mild asthmatics. AU - Blais,Christianne M, AU - Davis,Beth E, AU - Cockcroft,Donald W, Y1 - 2016/07/30/ PY - 2016/05/16/received PY - 2016/07/28/revised PY - 2016/07/29/accepted PY - 2016/9/1/entrez PY - 2016/9/1/pubmed PY - 2018/1/9/medline KW - Bronchoprotection KW - Glycopyrronium KW - Long acting muscarinic antagonists KW - Methacholine challenge testing KW - Tiotropium SP - 96 EP - 101 JF - Respiratory medicine JO - Respir Med VL - 118 N2 - UNLABELLED: The duration of bronchoprotection against methacholine-induced bronchoconstriction by long-acting muscarinic antagonists (LAMA's) in asthmatics and whether these drugs differ in their pharmacodynamic properties remain to be determined. The most recent published guidelines for methacholine challenge testing (MCT) suggest that LAMA's should be abstained from for 48 h prior to testing, perhaps one week in the case of tiotropium. The objectives were to determine and compare the duration of protection of a single dose of two different LAMA's, tiotropium and glycopyrronium, against methacholine-induced bronchoconstriction. Thirteen mild-to-moderate asthmatics [with a forced expiratory volume in 1 s (FEV1) > 65% of predicted and a baseline methacholine provocation concentration causing a 20% reduction in FEV1 (PC20) ≤ 8 mg/mL] completed this double-blind, double-dummy, crossover study. Methacholine challenges were performed before treatment (5 μg tiotropium or 50 μg glycopyrronium) and at 1, 24, 48, 72, 96 and 168 h post-treatment. The minimum duration between treatment administration was 11 days. Both drugs provided significant bronchoprotection, each producing greater than a 16-fold increase in mean PC20 by 1 h. Tiotropium still provided statistically significant protection at 7 days (p = 0.0282) while glycopyrronium provided bronchoprotection until day 7 (p = 0.0590). Tiotropium provided statistically superior bronchoprotection at 24 and 72 h compared to glycopyrronium. To minimize the occurrence of false negatives, MCT guidelines should be updated to recommend a minimum one-week abstinence period from all LAMA's. MCT was also able to statistically differentiate between tiotropium and glycopyrronium with respect to the degree and duration of bronchoprotection provided by each. CLINICAL TRIAL REGISTRATION NUMBER: NCT02622243. SN - 1532-3064 UR - https://www.unboundmedicine.com/medline/citation/27578477/Duration_of_bronchoprotection_of_the_long_acting_muscarinic_antagonists_tiotropium_&_glycopyrronium_against_methacholine_induced_bronchoconstriction_in_mild_asthmatics_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0954-6111(16)30173-1 DB - PRIME DP - Unbound Medicine ER -